FDA accepts first letter of intent (LOI) into the ISTAND Pilot Program for an organ-on-a-chip technology, a type of micro-physiological system (MPS), to study drug-induced liver injury (DILI) for certain drug candidates.
Similar Posts
Ultra Seal Corporation – 624650 – 09/25/2024
CGMP/Finished Pharmaceuticals/AdulteratedActivities Report of the Generic Drug Program (FY 2025) – FDARA Title VIII Sections 807 and 805
Section 807 of the FDA Reauthorization Act of 2017 (FDARA) requires the FDA to report on certain abbreviated new drug applications (ANDAs).Arterial Cannula Recall: Edwards Lifesciences Removes Arterial Cannula due to Risk of Wire Exposure
Edwards recalls arterial cannulae due to risk of wire exposure that may cause serious patient harm.Hello Cake, Inc. dba Hello Cake – 09/09/2025
Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the InternetWorld Market Recalls Emek Spread Pistachio Cacao Cream with Kadayif Due to Salmonella Contamination
World Market is recalling EMEK SPREAD PISTACHIO CACAO CREAM WITH KADAYIF, 9.7oz, Best Before: April 01, 2027, Batch Number: 250401 due to a potential contamination of Salmonella. Salmonella is an organism which can cause serious and sometimes fatal infections in young children, frail or elderly